An observational study in Familial Pulmonary Fibrosis, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Pulmonary Fibrosis with a site in Italy — 11 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Fibrosis · Italy.
Among the 31 studies in Pulmonary Fibrosis with a site in Italy, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2025, is one of 14 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 28th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →11 of the 31 studies in Pulmonary Fibrosis with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
University of Modena and Reggio Emilia · Sites in Italy
Ages 18+
University of Modena and Reggio Emilia · Sites in Italy
Ages 18–80
University Magna Graecia · Sites in Italy
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is below the median of 150 across 118 observational studies indexed under Pulmonary Fibrosis.
Median enrollment 320 across the 17 interventional studies, 90 across the 14 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.
Fondazione IRCCS Policlinico San Matteo di Pavia has 3 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Fibrosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571291Fondazione IRCCS Policlinico San Matteo di PaviaDEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS | 2026-12-31 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
| NCT05310669University of Modena and Reggio EmiliaInspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis | 2027-07-01 |
| NCT07373288University of Modena and Reggio EmiliaHOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary Fibrosis | 2027-07-01 |
| NCT06815185IRCCS Azienda Ospedaliero-Universitaria di BolognaRehabilitation Counselling for Patients with Interstitial Lung Disease | 2027-07-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies in Pulmonary Fibrosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary fibrosis (PF) is a progressive lung disease marked by tissue scarring and impaired breathing. Familial pulmonary fibrosis (FPF) makes up 10-20% of PF cases and shares features with idiopathic PF (IPF), but the genetic causes of FPF are not fully understood.
This study focuses on uncovering the genetic basis of FPF by analyzing families with multiple affected members. It targets genes involved in fibrogenesis and surfactant disorders, as familial cases often appear earlier and progress more rapidly than sporadic ones.
Understanding FPF genetics could:
In summary, the study aims to deepen our understanding of FPF genetics to improve diagnosis, counseling, and treatment for both familial and idiopathic forms of pulmonary fibrosis.
observational study , longitudinal retrospective
The study population includes individuals diagnosed with familial pulmonary fibrosis (FPF) and their first-degree relatives (affected and unaffected), as well as a comparison cohort of idiopathic pulmonary fibrosis (IPF) patients.
Participants will be recruited from two Italian centers:
SC Pneumologia, Fondazione IRCCS Policlinico San Matteo (Pavia) Azienda Ospedaliero Universitaria Careggi (Florence)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of Familial Pulmonary Fibrosis (FPF):
At least two individuals from the same family (first-degree relatives) diagnosed with pulmonary fibrosis based on clinical, radiological, or histopathological criteria (e.g., HRCT pattern consistent with usual interstitial pneumonia, UIP).
Definite or probable FPF diagnosis, according to international classification criteria and verified family history of disease.
Age:
Adults aged 18 years or older at the time of enrollment.
:
Ability and willingness to provide written informed consent (or consent provided by a legally authorized representative).
Willingness to participate in genetic testing, clinical evaluations, and longitudinal follow-up.
Availability of Family Members:
Affected family members with pulmonary fibrosis willing to provide blood samples and clinical information.
Unaffected first-degree relatives willing to participate in genetic testing and family history documentation.
Idiopathic Pulmonary Fibrosis (IPF) Cohort:
Individuals with a confirmed diagnosis of idiopathic pulmonary fibrosis (IPF) according to ATS/ERS 2018 criteria, enrolled as a comparative (non-familial) cohort.
Exclusion Criteria:
Non-Familial Pulmonary Fibrosis:
Individuals with isolated, sporadic pulmonary fibrosis (without a family history) who are not part of the defined IPF control group.
Other Significant Pulmonary Diseases:
Presence of pulmonary diseases unrelated to fibrosis (e.g., , asthma, cystic fibrosis, or active pulmonary infection).
Refusal or Withdrawal of Consent:
Individuals unwilling to provide or maintain for participation, genetic testing, or long-term data use.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Familial Pulmonary Fibrosis
idiopathic pulmonary fibrosis
Number and Type of Pathogenic or Likely Pathogenic Variants Identified by Next-Generation Sequencing (NGS)
dentification and classification of genetic variants detected in genes associated with familial pulmonary fibrosis (FPF) and surfactant metabolism (e.g., SFTPC, SFTPA2, ABCA3, MUC5B). Variants will be classified according to ACMG guidelines and reported as counts and frequencies in the study population.
Time frame: within 24 months of participant enrollment
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.
Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Policlinico San Matteo di Pavia →